The discovery that the epidermal growth factor (EGF) pathway in colorectal cancer was sensitive to inhibition by anti‐EGF receptor (EGFR) monoclonal antibodies (mAbs) led to the rapid development of panitumumab and cetuximab. Here, EGF is linked to colorectal cancer.